Study on Healing Effects of Bifidobacterium Infantis 35624 in Inflammatory and Energy Metabolism Parameters in High-Fat-Diet-Induced Obesity in Rat Model

Özlem Özdemir^1, , Çağrı Akalın², Fuat Ekiz³, Orhan Baş⁴ and Tülin Bayrak⁵

¹Department of InternalMedicine. MedicineFaculty of Ordu University, Ordu, Turkey

²Department of General Surgery, MedicineFaculty of Ordu University, Ordu, Turkey

³Department of Gastroenterelogy. Medical Park Ordu PrivateHospital, Ordu, Turkey

⁴Department of Anatomy, MedicineFaculty of Samsun University, Samsun, Turkey

⁵Department of MedicalBiochemistry, MedicineFaculty of Ordu University, Ordu, Turkey

Cite this paper:
Özlem Özdemir, Çağrı Akalın, Fuat Ekiz, Orhan Baş and Tülin Bayrak. Study on Healing Effects of Bifidobacterium Infantis 35624 in Inflammatory and Energy Metabolism Parameters in High-Fat-Diet-Induced Obesity in Rat Model. Journal of Food and Nutrition Research. 2025; 13(9):364-370. doi: 10.12691/jfnr-13-9-4

Abstract

Obesity is characterized by increased adipose tissue and low grade inflammation. The gut microbiota is closely associated with the obesity pathophysiology, so the probiotics; living microorganisms are questioned in terms of their effects on obesity related changes. Bifidobacterium infantis 35624 is used as a probiotic supplement in cases of digestive disorders. The aim of this study is to investigate its healing effect on the morphometric and inflammatory-energy metabolism responses in a high-fat diet-induced obese rat model. Three different nutritional groups, each consisting of eight rats, were followed for eight weeks. They received a conventional balanced diet, high-fat diet (HFD), and HFD with the supplementation of Bifidobacterium infantis 35624 respectively. The weight measurements were made weekly. At the end of the study, weight gains and body mass indexes were calculated. Plasma glucose, insulin, interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α) and glucagon-like peptide-1 (GLP-1) levels were evaluated. The weight changes of the HFD group showed a significant difference (p<0.001). HFD group with Bifidobacterium infantis 35624 supplementation showed significantly decreased body weight (p<0,001) and decreased plasma glucose, insulin, IL-6, TNF- α, GLP-1 levels compared to HFD group without probiotic supplementation (p<0,05). Bifidobacterium infantis 35624 may be a candidate probiotic to use in obesity management studies to maintain body weight, host energy metabolism, and inflammatory cytokine levels in high-fat diet nutrition.

Keywords:
High-fat-diet Bifidobacterium infantis 35624 Interleukin-6 Tumor necrosis factor alpha Obesity Glucagon-like peptide-1

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Caballero B. “Humans against Obesity: Who Will Win?” Adv Nutr,, 1;10. 4-9. Jan 2019.
[2]	Saltiel, A.R, and Olefsky, J.M. “Inflammatory mechanisms linking obesity and metabolic disease.” J Clın Invest., 127, 1–4. 2017
[3]	Drucker, D.J.,” Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.” Cell Metab., 3;27(4). 740-756. Apr 2018.
[4]	Popko, K., Gorska. E, Stelmaszczyk-Emmel. A., Plywaczewski, R., Stoklosa, A., Gorecka, D., Pyrzak, B., and Demkow, U. “Proinflammatory cytokines IL-6 and TNF-α and the development of inflammation in obese subjects.” Eur J Med Res. 4;15(Suppl 2). 120-122. Nov 2010.
[5]	Abenavoli, L., Scarpellini, E., Colica, C., Boccuto, L., Salehi, B., Sharifi-Rad, J. Aiello, V., Romano, B., De Lorenzo, A., Izzo, A.A., and Capasso, R.” Gut Microbiota and Obesity: A Role for Probiotics.” Nutrients., 7, 11(11). 2690. Nov 2019.
[6]	Gomaa, E.Z., Human gut microbiota/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek. 113(12). 2019-2040. Dec 2020.
[7]	Amabebe, E., Robert, F.O., Agbalalah, T.,,and Orubu, E.S.F.” Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism.” Br J Nutr., 28;123(10). 1127-1137.May 2020.
[8]	Yua, F., Ni, H., Asche, C.V., Kim, M., Walayat, S., and Ren, J. “Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.” Curr Med Res Opın., 33(7).1191-1197. Jul 2017.
[9]	Novelli, E.L.B., Diniz, Y.S., Galhardi, C.M., Ebaid, G.M.X., Rodrigues, H.G., Mani, F., Fernandes, A.A.H., Cicogna, A.C., and Filho, J.L.V.B. Anthropometrical parameters and markers of obesity in rats. Laboratory animals, 41(1). 111-119. Jan 2007.
[10]	Çelik, M.N.,and Söğüt, M.Ü. Probiotics Improve Chemerin Levels and Metabolic Syndrome Parameters in Obese Rats. Balkan Med J., 22;36(5): 270-275. 2019.
[11]	Dao, M.C., and Clément, K. Gut microbiota and obesity: concepts relevant to clinical care. Eur J Intern Med.; 48: 18–24. Feb 2018.
[12]	Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., and Gordon, J.I. An Obesity-Associated Gut Microbiome With Increased Capacity for Energy Harvest. Nature, 21; 444(7122). 1027–1031. Dec 2006.
[13]	Boroni Moreira, A.P., Fiche Salles, Teixeira. T., Gouveia Peluzio, M.d.C., and Gonçalves Alfenas, R.d.C. Gut microbiota and the development of obesity. Nutr Hosp., 27(5). 1408-1414. Sep-Oct 2012.
[14]	Zuo, H.J., Xie, Z.M., Zhang, W.W., Li, Y.R., Wang, W., Ding, X.B., and Pei, X.F. Gut bacteria alteration in obese people and its relationship with gene polymorphism. World J Gastroenterol., 28,17(8). 1076-1081. Feb 2011.
[15]	Sun, L., Ma, L., Ma, Y., Zhang, F., Zhao, C., and Nie, Y. Insights into the role of gut microbiota in obesity: pathogenesis, mechanisms, and therapeutic perspectives. Protein Cell, 9(5). 397–403. May 2018.
[16]	Stolarczyk, E. Adipose tissue inflammation in obesity: a metabolic or immune response? Curr Opin Pharmacol., 37. 35-40. Dec 2017.
[17]	Kern, P.A., Ranganathan, S., Li, C., and Wood, L. Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab., 280(5). 745-751. May 2001.
[18]	Bagchi, D.P., and MacDougald, O.A. Identification and Dissection of Diverse Mouse Adipose Depots. J Vis Exp.,.11:(149):10.3791/59499. Jul 2019.
[19]	Fain, J.N. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: A review. Mediators Inflamm., 2010. 513948. 2010.
[20]	Moghbeli, M., Khedmatgozar, H., Yadegari, M., Avan, A., Ferns, G.A., and Mobarhan, M.G. Cytokines and the immune response in obesity-related disorders. Adv Clin Chem., 101, 135-168. 2021
[21]	Khathlan NA. Association of inflammatory cytokines with obesity and pulmonary function testing. PLoS One, 22;18(11):e0294592. Nov 2023.
[22]	Stanek, A., Brożyna-Tkaczyk, K., and Myśliński,,W. The role of obesity-induced perivascular adipose tissue dysfunction in vascular homeostasis. Nutrients. 28;13(11):3843. Oct 2021.
[23]	Soták, M., Clark, M., Suur,  B.E., and Börgeson, E. Inflammation and resolution in obesity. Nat Rev Endocrinol., 21(1):45-61. Jan 2025.
[24]	Steinerta, A., Radulovicc, K., and Niess, J.H. Gastrointestinal tract: the leading role of mucosalimmunity. Swiss Med Wkly., 5:146:w14293. Apr 2016.
[25]	Tilg, H., and Kaser, A. Gut microbiome, obesity, and metabolic dysfunction. J Clın Inves., 121: 2126-2132. Jun 2011.
[26]	Mohammad, S., and Thiemermann, C. Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions. Front Immunol., 11: 594150. Jan 2021.
[27]	Cani, P.D., Delzenne, N.M., Amar, J., and Burcelin, R.. Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feding. Pathol Biol (Paris). 56(5):305-309. Jul 2008.
[28]	Amar, J., Burcelin, R., Ruidavets, J.B., Cani, P.D, Fauvel, J., Alessi, M.C., Chamontin, B.., and Ferriéres, J. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr.; 87(5): 1219-1223. May 2008.
[29]	Mehta, N.N., McGillicuddy, F.C., Anderson, P.D., Hinkle, C.C., Shah, R., Pruscino, L., Tabita-Martinez, J., Sellers, K.F., Rickels, M.R., and Reilly, M.P. Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes., 59: 172-181. Jan 2010.
[30]	Cani, P.D., Neyrinck, A.M., Fava, F., Knauf, C., Burcelin, R.G., Tuohy, K.M., Gibson, G..R., and Delzenne, N.E. Selective increases of bifidobacteria in gut microflora improves high-fat diet induced diabetes in mice through a mechanism associated with endotoxemia. Diabetologia., 50(11): 2374–2383. Nov 2007.
[31]	Hira, T., Pinyo, J., and Hara, H. What Is GLP-1 Really Doing in Obesity? Trends Endocrın Met., 31(2): 71-80. Feb 2020.
[32]	Cho, Y.M., Fujita, Y., and Kieffer, T.J. Glucagon-like peptide-1: glucose homeostasis and beyond. Annu Rev Physıol.; 76: 535-559. 2014.
[33]	Chen, Q., Gao, Y., Li, F., and Yuan, L. The role of gut–islet axis in pancreatic islet function and glucose homeostasis. Diabetes Obes Metab., 27(4):1676-1692. Apr 2025.
[34]	Adam, T.C., Jocken, J., and Westerterp-Plantenga, M.S. Decreased glucagon-like peptide 1 release after weight loss in overweight/obese subjects. Obes Res. 13(4): 710-716. Apr 2005.
[35]	Muscogiuri, G., Balercia, G., Barrea, L., Cignarelli, A., Giorgino, F., Holst, J.J, Laudisio, D., Orio, F., Tirabassi, G., and Colao, A. Gut: A key player in the pathogenesis of type 2 diabetes? Crit Rev Food Sci Nutr., 24: 1294-1309. May 2018.
[36]	Cerdó, T., García-Santos, J.A., Bermúdez, M.G., and Campoy, C. The Role of Probiotics and Prebiotics in the Prevention and Treatment of Obesity. Nutrients., 15, 11(3): 635-666. Mar 2019.
[37]	Saadati, S., Naseri, K., Asbaghi, O., Yousefi, M., Golalipour, E., and De Courten, B. Beneficial effects of the probiotics and synbiotics supplementation on anthropometric indices and body composition in adults: A systematic review and meta-analysis. Obes Rev., 25(3):e13667. Mar 2024
[38]	Mazloom, K., Siddiqi, I., and Covasa, M. Probiotics: How Effective Are They in the Fight against Obesity? Nutrients., 24;11(2):258. Jan 2019.
[39]	Di Gioia, D., Aloisio, I., Mazzola, G., and Biavati, B. Bifidobacteria: their impact on gut microbiota composition and their applications as probiotics in infants. Applied Microbiology and Biotechnology, 98(2). 563–577.Jan 2014.
[40]	An, H.M., Park, S.Y., Lee, D.K., Kim, J.R., Cha, M.K., Lee, S.W., Lim, H.T., Kim, K.J., and Ha, N.J. Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat diet-induced obese rats. Lipids Health Dis., 10: 116. Jul 2011.
[41]	Chung LE, T.K., Hosaka, T., Tam Le, T.T., Nguyen, T.G., Tran, Q.B., Hao Le, T.H., and Da Pham, X. Oral administration of Bifidobacterium spp. improves insulin resistance, induces adiponectin, and prevents inflammatory adipokine expressions. Biomed Res., 35(5). 303-310. 2014.
[42]	Groeger, D., O’Mahony, L., Murphy, E.F., Bourke, J.F., Dinan, T.G., Kiely, B., Shanahan, F.,and M Quigley, F. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes, 4(4). 325-339. 2013